Thrombus - 2007

Role of the JAK2 mutation in abdominal vein thrombosis
Catherine N Bagot, Raj K Patel and Roopen Arya
pp 1-3
Venous thrombosis in the portal, mesenteric and hepatic veins are rare but severe conditions often affecting young patients. Thrombosis of the hepatic veins results in Budd–Chiari syndrome (BCS), which has a heterogeneous clinical presentation. Portal vein thrombosis (PVT) presents with complications of portal hypertension. Extension of thrombosis into the mesenteric veins may cause intestinal infarction. Mortality rates are 5–38% (BCS) and 10–25% (PVT), with prognosis highly dependent on patient age at presentation and the underlying aetiology of the thrombotic event. Diagnosis is by Doppler ultrasonography, computerised tomography (CT) (see Figure 1) or MRI.
Comment: Look and learn
David Fitzmaurice and Ellen Murray
pp 2-2
The last 20 years have seen a revolution in service delivery for patients receiving oral anticoagulation therapy, principally warfarin, in the UK. The main driver for this revolution has been the increasing number of patients with atrial fibrillation who are receiving warfarin as thromboprophylaxis. There is compelling evidence for the use of warfarin in atrial fibrillation, with a reduction in stroke rates of about 60% and a reduction in mortality of about 40%.
Predicting the recurrence of thrombosis
Ian Jennings
pp 4-5
Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the Western world, with an annual incidence in the general population estimated to be 1:1,000. A number of factors, both inherited and acquired, are known to increase the risk of thrombosis (see Table 1). Predicting a first thrombotic event in asymptomatic individuals is problematic. Population screening for thrombophilia cannot be justified on the grounds of cost or clinical utility.
Obesity and venous thromboembolism
Vikramajit Singh, Paneesha Shankaranarayana and Peter Rose
pp 6-7
In 1856, Rudolph Virchow identified three primary risk factors – classically described as Virchow’s triad – for venous thromboembolism (VTE): venous stasis, hypercoagulability, and endothelial injury. Since then, many other risk factors have been identified. The magnitude of these vary, and the independence of each is, at best, uncertain. Table 1 lists both major and minor risk factors.
Resistance to antiplatelet agents
Paul Harrison
pp 8-11
As platelets are firmly implicated in the pathology of atherosclerosis and arterial thrombosis, antiplatelet therapy forms an important and effective component of both treatment and prophylactic strategies.1 Many established antiplatelet drugs are traditionally administered at standard doses without monitoring of their efficacy.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)